Drug Patents owned by Lab Hra Pharma

1. Drug name - ELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844510 LAB HRA PHARMA Ulipristal acetate tablets Dec, 2028

(6 years from now)

US8735380 LAB HRA PHARMA Ulipristal acetate tablets Feb, 2029

(6 years from now)

US10159681 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US10772897 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US9283233 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US8512745 LAB HRA PHARMA Ulipristal acetate tablets Jun, 2030

(7 years from now)

US8426392 LAB HRA PHARMA Method for providing emergency contraception Jun, 2030

(7 years from now)

US8962603 LAB HRA PHARMA Method for post coital contraception in overweight or obese female subjects using ulipristal acetate Jun, 2030

(7 years from now)

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.